All patients in this study successfully completed the initial intravesical injection of type A botulinum toxin, with a total dose of 100 U. Despite a few patients experiencing mild gross hematuria and urinary tract infections, no overt symptoms of bladder perforation, voiding difficulties, urinary retention, or allergic reactions were observed. This evidence concerns the gene SGCG and urinary tract infection.